Comparison of resource use by COPD patients on inhaled therapies with long-acting bronchodilators: A database study

BMC Pulmonary Medicine

Volumn 11, Issue , 2011, Pages

  Kozma, Chris M ^a   Paris, Andrew L ^b   Plauschinat, Craig A ^c   Slaton, Terra ^d   Mackowiak, John I ^e  

^a CK Consulting   (United States)

^b Vigilytics LLC   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d Center for Outcomes Research ^*  (United States)

^e Center for Outcomes Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CORTICOSTEROID; FLUTICASONE; FORMOTEROL; METHYLXANTHINE; MUSCARINIC RECEPTOR BLOCKING AGENT; SALMETEROL; TIOTROPIUM BROMIDE;

ADULT; ANALYSIS OF VARIANCE; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DEMOGRAPHY; DRUG COST; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROPENSITY SCORE; RETROSPECTIVE STUDY; AGED; ARTIFICIAL VENTILATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; DELAYED RELEASE FORMULATION; ECONOMICS; FACTUAL DATABASE; FOLLOW UP; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, INHALATION; AGED; BRONCHODILATOR AGENTS; DATABASES, FACTUAL; DELAYED-ACTION PREPARATIONS; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY THERAPY; RETROSPECTIVE STUDIES;

EID: 84055223645     PISSN: None     EISSN: 14712466     Source Type: Journal    
DOI: 10.1186/1471-2466-11-61     Document Type: Article

References (12)

1. The Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2010. , http://www.goldcopd.org
2. Combivent Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest 1994, 1005(5):1411-9.
3. Jones PW, Willitis LR, Burge PS, Calverley PM. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 2003, 21:68-73. 10.1183/09031936.03.00013303, 12570111.
4. Gaebel K, McIvor RA, Xie F, Blackhouse G, Robertson D, Assasi N, Hernandez P, Goeree R. Triple therapy for the management of COPD: A review. COPD 2011, 8:206-43. 10.3109/15412555.2011.560131, 21513437.
5. Jones PW, Willitis LR, Burge PS, Calverley PM. Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 2003, 21:68-73. 10.1183/09031936.03.00013303, 12570111.
6. Calverley PM, Anderson JA, Celli B, , et al. TORCH Investigators Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N England J Med 2007, 356:775-89. TORCH Investigators.
7. Penning-van Beest F, van Herk-Sukel M, Gale R, Lammers JW, Herings R. Three-year dispensing patterns with long-acting inhaled drugs in COPD: a database analysis. Respir Med 2011, (105):259-65.
8. Kozma CM, Reeder CE, Schulz RM. Economic, clinical, and humanistic outcomes: a planning model for pharmacoeconomic research. Clin Ther 1993, 15:1121-32. discussion 1120.
9. Jones R, Ostrem A. Optimizing pharmacological maintenance treatment for chronic obstructive pulmonary disease in primary care. Prim Care Respir J 2010, 20:33-45.
10. Rosenbaum PR, Rubin DB. Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. Am Stat 1985, 39:33-8.
11. Imbens GW. The role of the propensity score in estimating dose response functions. Biometrika 2000, 87:706-10.
12. The Bureau of Labor Statistics, All Urban Consumers, medical services component. , http://www.bls.gov